Finance

Lists
RYTM:NASDAQ
Rhythm Pharmaceuticals Inc
$102.20
+1.13%
(+1.14) 1D
$103.00
+0.78% (+0.80)
Pre-market
Closed: Sep 10, 4:00:00 PM GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for RYTM...
Open
$99.88
High
$102.89
Low
$99.88
Mkt. cap
7.04B
Avg. vol.
591.23K
Volume
2.57K
52-wk high
$122.20
52-wk low
$74.51
EPS
-$3.12
Beta
1.97
Shares outstanding
68.85M
No. of employees
414
Open
$99.88
High
$102.89
Low
$99.88
Mkt. cap
7.04B
Avg. vol.
591.23K
Volume
2.57K
52-wk high
$122.20
52-wk low
$74.51
EPS
-$3.12
Beta
1.97
Shares outstanding
68.85M
No. of employees
414
News stories
From web sources and news partners
About Rhythm Pharmaceuticals Inc
CEO-
Employees414
FoundedNov 2008
HeadquartersBoston, Massachusetts, United States
SectorBiotechnology
Websiterhythmtx.com
Analyst ratings
Based on 16 analysts giving stock ratings to RYTM in the past 3 months
Strong buy
Buy
15
Hold
1
Sell
0
12-month forecast
Based on 16 Wall Street analysts offering 12 month price targets for RYTM in the last 3 months.
Highest
Current $102.20
$160.00 (+56.56%)
Average
$141.06 (+38.02%)
Lowest
$105.00 (+2.74%)
Analyst
Recommendation
Action
Price target
Projected
Date
David Hoang
Deutsche Bank
Hold
Initiated
$120.00
+17.4%
08/27/2026
Michael Ulz
Morgan Stanley
Buy
Reiterated
$150.00
+46.8%
08/24/2026
Seamus Fernandez
Guggenheim
Buy
Reiterated
$143.00
+39.9%
08/24/2026
Priyanka Grover
J.P. Morgan
Buy
Reiterated
$146.00
+42.9%
08/10/2026
Lisa Walter
RBC Capital
Buy
Reiterated
$155.00
+51.7%
08/04/2026
Whitney Ijem
Canaccord Genuity
Buy
Maintained
$154.00
+50.7%
08/05/2026
Samantha Semenkow
Citi
Buy
Maintained
$143.00
+39.9%
08/05/2026
Jonathan Wolleben
Citizens JMP
Buy
Maintained
$160.00
+56.6%
08/05/2026
Tazeen Ahmad
Bank of America Securities
Buy
Reiterated
$149.00
+45.8%
08/04/2026
Phil Nadeau
TD Cowen
Buy
Reiterated
$130.00
+27.2%
08/04/2026
Joseph Stringer
Needham
Buy
Maintained
$130.00
+27.2%
08/04/2026
Unknown Analyst
J.P. Morgan
Buy
Initiated
$145.00
+41.9%
07/27/2026
Derek Archila
Wells Fargo
Buy
Reiterated
$155.00
+51.7%
07/16/2026
Dennis Ding
Jefferies
Buy
Maintained
$125.00
+22.3%
06/15/2026
Corinne Johnson
Goldman Sachs
Buy
Maintained
$159.00
+55.6%
06/14/2026
Paul Matteis
Stifel Nicolaus
Buy
Reiterated
$133.00
+30.1%
06/15/2026
Ram Selvaraju
H.C. Wainwright
Buy
Reiterated
$105.00
+2.7%
06/15/2026
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in USD
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Revenue
51.30M
57.25M
60.11M
71.26M
Cost of goods sold
5.50M
4.80M
7.16M
8.93M
Cost of revenue
5.50M
4.80M
7.16M
8.93M
Research and development expenses
46.03M
42.03M
41.72M
43.43M
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
52.42M
57.48M
63.59M
67.45M
Operating expense
98.45M
99.51M
105.32M
110.88M
Total operating expenses
103.95M
104.32M
112.47M
119.81M
Operating income
-52.65M
-47.06M
-52.36M
-48.55M
Other non operating income
274.00K
57.00K
-3.10M
1.02M
EBT including unusual items
-52.79M
-47.54M
-55.09M
-48.85M
EBT excluding unusual items
-52.79M
-47.54M
-55.09M
-48.85M
Income tax expense
111.00K
-31.00K
545.00K
444.00K
Effective tax rate
-0.21%
0.07%
-0.99%
-0.91%
Other operating expenses
-
-
-
-
Net income
-52.90M
-47.50M
-55.64M
-49.30M
Net profit margin
-103.13%
-82.97%
-92.56%
-69.19%
Earnings per share
-0.82
-0.73
-0.83
-0.73
Interest and investment income
4.33M
4.08M
3.55M
3.22M
Interest expense
-4.74M
-4.62M
-4.58M
-4.54M
Net interest expenses
-414.00K
-530.00K
-1.03M
-1.32M
Depreciation and amortization charges
-
-
-
-
EBITDA
-52.35M
-46.79M
-52.11M
-48.30M
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google apps